» Articles » PMID: 29431110

The Personal Genome Project Canada: Findings from Whole Genome Sequences of the Inaugural 56 Participants

Abstract

Background: The Personal Genome Project Canada is a comprehensive public data resource that integrates whole genome sequencing data and health information. We describe genomic variation identified in the initial recruitment cohort of 56 volunteers.

Methods: Volunteers were screened for eligibility and provided informed consent for open data sharing. Using blood DNA, we performed whole genome sequencing and identified all possible classes of DNA variants. A genetic counsellor explained the implication of the results to each participant.

Results: Whole genome sequencing of the first 56 participants identified 207 662 805 sequence variants and 27 494 copy number variations. We analyzed a prioritized disease-associated data set ( = 1606 variants) according to standardized guidelines, and interpreted 19 variants in 14 participants (25%) as having obvious health implications. Six of these variants (e.g., in or mosaic loss of an X chromosome) were pathogenic or likely pathogenic. Seven were risk factors for cancer, cardiovascular or neurobehavioural conditions. Four other variants - associated with cancer, cardiac or neurodegenerative phenotypes - remained of uncertain significance because of discrepancies among databases. We also identified a large structural chromosome aberration and a likely pathogenic mitochondrial variant. There were 172 recessive disease alleles (e.g., 5 individuals carried mutations for cystic fibrosis). Pharmacogenomics analyses revealed another 3.9 potentially relevant genotypes per individual.

Interpretation: Our analyses identified a spectrum of genetic variants with potential health impact in 25% of participants. When also considering recessive alleles and variants with potential pharmacologic relevance, all 56 participants had medically relevant findings. Although access is mostly limited to research, whole genome sequencing can provide specific and novel information with the potential of major impact for health care.

Citing Articles

Myosin inhibitor reverses hypertrophic cardiomyopathy in genotypically diverse pediatric iPSC-cardiomyocytes to mirror variant correction.

Kinnear C, Said A, Meng G, Zhao Y, Wang E, Rafatian N Cell Rep Med. 2024; 5(5):101520.

PMID: 38642550 PMC: 11148569. DOI: 10.1016/j.xcrm.2024.101520.


The Data and Research Center: Creating a Secure, Scalable, and Sustainable Ecosystem for Biomedical Research.

Mayo K, Basford M, Carroll R, Dillon M, Fullen H, Leung J Annu Rev Biomed Data Sci. 2023; 6:443-464.

PMID: 37561600 PMC: 11157478. DOI: 10.1146/annurev-biodatasci-122120-104825.


Impact of stress on cardiac phenotypes in mice harboring an ankyrin-B disease variant.

Wallace M, Malhotra N, Mariangelo J, Stevens T, Young L, Antwi-Boasiako S J Biol Chem. 2023; 299(6):104818.

PMID: 37182735 PMC: 10318515. DOI: 10.1016/j.jbc.2023.104818.


Compound heterozygous loss-of-function variants in BRAT1 cause lethal neonatal rigidity and multifocal seizure syndrome.

Li S, Yu S, Zhang Y, Wang Y, Jiang X, Wu C Mol Genet Genomic Med. 2022; 11(1):e2092.

PMID: 36367347 PMC: 9834191. DOI: 10.1002/mgg3.2092.


Pharmacogenetic profiling via genome sequencing in children with medical complexity.

Pan A, Scodellaro S, Khan T, Ushcatz I, Wu W, Curtis M Pediatr Res. 2022; 93(4):905-910.

PMID: 36167815 PMC: 10033400. DOI: 10.1038/s41390-022-02313-3.


References
1.
Reymer P, Groenemeyer B, Gagne E, Miao L, Appelman E, Seidel J . A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. Hum Mol Genet. 1995; 4(9):1543-9. DOI: 10.1093/hmg/4.9.1543. View

2.
Reymer P, Gagne E, Groenemeyer B, Zhang H, Forsyth I, Jansen H . A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat Genet. 1995; 10(1):28-34. DOI: 10.1038/ng0595-28. View

3.
Russell L, Strike P, Browne C, Jacobs P . X chromosome loss and ageing. Cytogenet Genome Res. 2007; 116(3):181-5. DOI: 10.1159/000098184. View

4.
Linderman M, Nielsen D, Green R . Personal Genome Sequencing in Ostensibly Healthy Individuals and the PeopleSeq Consortium. J Pers Med. 2016; 6(2). PMC: 4932461. DOI: 10.3390/jpm6020014. View

5.
Whirl-Carrillo M, McDonagh E, Hebert J, Gong L, Sangkuhl K, Thorn C . Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012; 92(4):414-7. PMC: 3660037. DOI: 10.1038/clpt.2012.96. View